The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primatesJonathan Zalevsky, Chris E. Lawrence, Eugene A. Zhukovsky et al.|Blood|2008Cited by 101
XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.Chris E. Lawrence, David F. Carmichael, Phil W. Hammond et al.|Blood|2007Cited by 11
Evaluation of the Pharmacokinetics, Immunogenicity, and Safety of XmAb®2513 in the Ongoing Study XmAb2513-01: A Phase 1 Study of Every Other Week XmAb2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients with Hodgkin Lymphoma or Anaplastic Large Cell LymphomaAnas Younes, Jeffrey D. Bloss, Jonathan Zalevsky et al.|Blood|2008Cited by 9
XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell MalignanciesChris E. Lawrence, David F. Carmichael, John R. Desjarlais et al.|Blood|2008Cited by 1